BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GC304 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GC304\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05860569-8608@assetmemo.bio
DTSTAMP:20261121T005629Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:GC304: Phase 1 readout est. (NCT05860569)
DESCRIPTION:GC304\, phase 1.\nStudy: Safety Evaluation of Gene Therapy Drug
  in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent 
 Pancreatitis\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/gc304#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05860569
URL:https://assetmemo.bio/drug/gc304#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
